Paris, December 17, 2009 - Cellectis bioresearch, a specialist in genome
customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), has today
announced the launch of cGPS® Custom HEK293, its first research kit that can be
used on cell lines derived from human material.
The new cGPS® Custom kit will allow scientists to control the expression of any
gene of interest in the human embryonic kidney cell line, HEK293. Specifically, the
kit allows rapid, efficient and precise gene integration and expression, enabling high
quality research into the mechanisms of human gene function and its involvement in
disease.
The cGPS® Custom HEK293 kit has been initially validated in HEK293 cells,
however it also has the potential to be used in any cell line derived from human
material. During 2010 Cellectis bioresearch will focus on expanding its series of
ready-to-use products for the functional genetics market by validating cGPS®
Custom HEK293, and its associated simple operating protocols, in other human cell
lines.
“We are very excited to reach our goal of launching six new bioresearch kits this
year,” said Luc Selig, VP Sales & Marketing for Cellectis bioresearch. “We are
looking forward to bringing a wider range of kits to the market next year”.
Cellectis bioresearch currently supplies two targeted integration product lines –
cGPS® (cellular Genome Positioning System) and cGPS® Custom – both of which
can be purchased via www.cellectis-bioresearch.com.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in
June 2008. It provides life science researchers with genome customization kits for rapid,
efficient gene integration at a precise genomic position in a given cell type.
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company
focuses on developing and producing custom meganucleases for use in in vivo genome
surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors.
Worldwide, Cellectis has entered into more than 50 agreements with major players in the
pharma, biotech and agrobiotech industries and has over 20 collaborations with academic
research groups.
To date, Cellectis has raised over €70 million in both equity operations and public financing
and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more
information on Cellectis, visit our website: www.cellectis.com
